Findings

What do systematic reviews say?

86 questions · 87 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 36 · 41.4%GRADE not reported 5 · 5.7%Very low 27 · 31%Low 13 · 14.9%Moderate 6 · 6.9%High 0 · 0%

Hypertonic saline vs mannitol

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Mortality (short‐term) · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes mortality (short‐term) compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 0.33
2 studies · 70 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Mortality at 6 months · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes mortality at 6 months compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 0.84 [0.46, 1.55]
2 studies · 85 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Glasgow Outcome Scale: poor outcome at 6 months · people with acute traumatic brain injury

It is very uncertain whether hypertonic saline changes glasgow Outcome Scale: poor outcome at 6 months compared with other intracranial pressure‐lowering agents (very low certainty).

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
RR 1.09 [0.82, 1.44]
2 studies · 85 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Uncontrolled ICP during treatment · people with acute traumatic brain injury

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 287 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

A rebound phenomenon during treatment · people with acute traumatic brain injury

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Hypertonic saline vs other intracranial pressure‐lowering agents

Pulmonary oedema · people with acute traumatic brain injury

The review found no eligible studies for this question.

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs other intracranial pressure‐lowering agents

Acute renal failure during treatment · people with acute traumatic brain injury

The review found no eligible studies for this question.

1 finding from 1 review

Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 246 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

LCI · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

All‐cause mortality · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

Measures of sputum clearance · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

Pulmonary exacerbations · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

Hypertonic saline 3% to 7% showed no clear difference in pulmonary exacerbations compared with isotonic saline (low certainty).

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
HR 0.86 [0.57, 1.3]
1 study · 132 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

FEV1 · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 134 participants
Low

Hypertonic saline 3% to 7% vs Normal saline

LCI · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

All‐cause mortality · adults and children with cystic fibrosis (stable lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

Measures of sputum clearance · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 80 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

Pulmonary exacerbations · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 607 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

Adverse events · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 513 participants
Low